Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EBIT (2019 - 2025)

Cyclerion Therapeutics has reported EBIT over the past 7 years, most recently at -$1.0 million for Q3 2025.

  • Quarterly results put EBIT at -$1.0 million for Q3 2025, up 10.82% from a year ago — trailing twelve months through Sep 2025 was -$3.6 million (up 38.68% YoY), and the annual figure for FY2024 was -$3.6 million, up 71.99%.
  • EBIT for Q3 2025 was -$1.0 million at Cyclerion Therapeutics, up from -$1.7 million in the prior quarter.
  • Over the last five years, EBIT for CYCN hit a ceiling of $502000.0 in Q4 2024 and a floor of -$16.2 million in Q2 2021.
  • Median EBIT over the past 5 years was -$3.3 million (2023), compared with a mean of -$5.9 million.
  • Biggest five-year swings in EBIT: crashed 33.13% in 2023 and later surged 127.97% in 2024.
  • Cyclerion Therapeutics' EBIT stood at -$14.3 million in 2021, then surged by 68.93% to -$4.5 million in 2022, then surged by 59.71% to -$1.8 million in 2023, then surged by 127.97% to $502000.0 in 2024, then tumbled by 300.4% to -$1.0 million in 2025.
  • The last three reported values for EBIT were -$1.0 million (Q3 2025), -$1.7 million (Q2 2025), and -$1.5 million (Q1 2025) per Business Quant data.